Drugs / WD-890
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06506591 | Oct 2023 → Aug 2024 | — | Zhejiang Wenda Pharma Technology LTD. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06912165 | Dec 2024 → Oct 2025 overdue | — | Zhejiang Wenda Pharma Technology LTD. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07672561 | Mar → Nov 2026 expected | psoriasis | Zhejiang Wenda Pharma Technology LTD. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WD-890 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06506591 ↗ |
| Route | Oral | “Take a fixed dose of WD-890 tablets orally” NCT06506591 ↗ |